Technical Analysis for ALLO - Allogene Therapeutics, Inc.

Grade Last Price % Change Price Change
grade C 30.38 -1.01% -0.31
ALLO closed down 3.7 percent on Wednesday, February 20, 2019, on 65 percent of normal volume.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Up Down
See historical ALLO trend table...

Date Alert Name Type % Chg
Feb 20 MACD Bearish Signal Line Cross Bearish -1.01%
Feb 20 Outside Day Range Expansion -1.01%
Feb 15 Slingshot Bullish Bullish Swing Setup -2.75%
Feb 15 Upper Bollinger Band Walk Strength -2.75%
Feb 14 Slingshot Bullish Bullish Swing Setup -2.44%
Feb 14 Upper Bollinger Band Walk Strength -2.44%
Feb 14 Outside Day Range Expansion -2.44%
Feb 14 Upper Bollinger Band Touch Strength -2.44%
Feb 13 NR7 Range Contraction -4.88%
Feb 13 Upper Bollinger Band Walk Strength -4.88%

Older signals for ALLO ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: ???
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.
Biotechnology Cancer Life Sciences Stem Cells Cell Biology Therapy Cell Therapy Stage Biotechnology Therapies For Cancer Kite Pharma Adoptive Cell Transfer
Is ALLO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Feb 20 Meet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space
Feb 20 Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
Feb 8 4 Disruptive Healthcare Stocks You've Never Heard Of
Feb 5 Allogene Therapeutics Announces February and March 2019 Investor Conference Schedule
Jan 29 What's next for this slow-moving Peninsula biotech IPO?
Jan 28 Allogene Therapeutics, in Collaboration with Servier, Announces FDA Clearance of the IND for ALLO-501, an anti-CD19 Allogeneic CAR T (AlloCAR T™) Therapy
Jan 18 KPMG's former S.F. head Debbie Messemer lands on leading fintech's board
Jan 17 East Bay accounting firm’s new leader says improv upped his presentation skills
Jan 14 Today's Research Reports on Trending Tickers: Novavax and Allogene Therapeutics
Jan 9 Cell therapy pioneer eyes Bay Area manufacturing
See more ALLO news...
Indicators
Indicator Value
52 Week High 35.55
52 Week Low 21.67
Average Volume 446,729
200-Day Moving Average 0.0
50-Day Moving Average 28.1642
20-Day Moving Average 30.455
10-Day Moving Average 30.974
Average True Range 1.523
ADX 25.66
+DI 17.7362
-DI 15.2524
Chandelier Exit (Long, 3 ATRs ) 27.901
Chandelier Exit (Short, 3 ATRs ) 31.609
Upper Bollinger Band 32.4976
Lower Bollinger Band 28.4124
Percent B (%b) 0.56
BandWidth 13.413889
MACD Line 0.8492
MACD Signal Line 0.9013
MACD Histogram -0.0521
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.21
Resistance 3 (R3) 33.44 32.84 32.79
Resistance 2 (R2) 32.84 32.19 32.72 32.65
Resistance 1 (R1) 31.76 31.80 31.46 31.53 32.51
Pivot Point 31.16 31.16 31.01 31.04 31.16
Support 1 (S1) 30.08 30.51 29.78 29.85 28.87
Support 2 (S2) 29.48 30.12 29.36 28.73
Support 3 (S3) 28.40 29.48 28.59
Support 4 (S4) 28.17